Recommendations of the Advisory Committee on Immunization Practices for Use of a Hepatitis B Vaccine with a Novel Adjuvant

Schillie, Sarah; Harris, Aaron M.; Link‐Gelles, Ruth; Romero, José R.; Ward, John W.; Nelson, Noele P.

doi:10.15585/mmwr.mm6715a5

Cited by 159 publications

(131 citation statements)

References 8 publications

Supporting

Mentioning

130

Contrasting

Unclassified

Order By: Relevance

“…This vaccine was approved in 2018 for all persons aged 18 years or older for vaccination against HBV. (49)…”

Section: Advances In Vaccinationmentioning

confidence: 99%

Chronic Viral Hepatitis: Current Management and Future Directions

Reau

2020

Hepatol Commun

View full text Add to dashboard Cite

The past decade has seen transformation in the strategies for identifying and managing viral hepatitis, most dramatically the transformation of hepatitis C virus from a mostly chronic affliction to a curable disease that is accessible to wide populations through direct‐acting antiviral therapies. More recently, shifting of hepatitis C virus burden to younger patients driven by intravenous drug use has shaped screening recommendations. Future work focusing on effective screening, linkage to care, treatment initiation, and post‐cure management will allow countries to work toward meeting goals of eliminating viral hepatitis as a major public health threat. Concurrently, hepatitis B virus has also seen advances in management using oral nucleos(t)ide therapies with high‐resistance barriers. However, virologic cure remains elusive in the setting of viral genetic persistence within the hepatocyte nucleus, even with suppressive antiviral therapy. Future directions include a refined definition of “cure,” new biomarkers, and development of therapies targeting multiple pathways in the viral pathogenic and replication pathway. Progress is additionally being made on the management of hepatitis D infection. This review summarizes the recent evolution in disease characteristics, associated affected population, and changes in our understanding of management for these infections. We also discuss future directions in the management of viral hepatitis, including discussion on issues related to management before and after antiviral therapy. Conclusion: We summarize recent advances in the identification and management of viral hepatitis, which hold the potential to markedly reduce disease burden and therefore associated liver‐related complications. However further work is needed to adequately identify and manage these diseases.

show abstract

“…This vaccine was approved in 2018 for all persons aged 18 years or older for vaccination against HBV. (49)…”

Section: Advances In Vaccinationmentioning

confidence: 99%

Chronic Viral Hepatitis: Current Management and Future Directions

Reau

2020

Hepatol Commun

View full text Add to dashboard Cite

show abstract

“…Vaccine changes in the 2019 immunization schedule for children and adolescents aged ≤18 years include new or revised ACIP recommendations for hepatitis A vaccine (HepA), hepatitis B vaccine (Hep B), influenza vaccine, and tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap), as well as clarification of the recommendations for inactivated poliovirus vaccines (IPV).…”

Section: Vaccine Changes In the 2019 Immunization Schedule For Childrmentioning

confidence: 99%

Advisory Committee on Immunization Practices recommended immunization schedule for children and adolescents aged 18 years or younger — United States, 2019

Robinson

Bernstein

Romero

et al. 2019

American Journal of Transplantation

View full text Add to dashboard Cite

show abstract

“…Boosting with a protein subunit-based vaccine implicates the use of adjuvants to increase immunogenicity. Newly approved adjuvants for humans are focused on TLR ligands like MPLA (TLR4) in the HPV vaccine and ODN-CpG (TLR9) in the new HBV vaccine (15). Between them, the efficacy of CpG has been extensively studied in anti-T. cruzi vaccines appearing as an acceptable candidate (8,13,16,17).…”

Section: Introductionmentioning

confidence: 99%

Mucosal Heterologous Prime/Boost Vaccination Induces Polyfunctional Systemic Immunity, Improving Protection Against Trypanosoma cruzi

et al. 2020

View full text Add to dashboard Cite

There are several unmet needs in modern immunology. Among them, vaccines against parasitic diseases and chronic infections lead. Trypanosoma cruzi, the causative agent of Chagas disease, is an excellent example of a silent parasitic invasion that affects millions of people worldwide due to its progression into the symptomatic chronic phase of infection. In search for novel vaccine candidates, we have previously introduced Traspain, an engineered trivalent immunogen that was designed to address some of the known mechanisms of T. cruzi immune evasion. Here, we analyzed its performance in different DNA prime/protein boost protocols and characterized the systemic immune response associated with diverse levels of protection. Formulations that include a STING agonist, like c-di-AMP in the boost doses, were able to prime a Th1/Th17 immune response. Moreover, comparison between them showed that vaccines that were able to prime polyfunctional cell-mediated immunity at the CD4 and CD8 compartment enhanced protection levels in the murine model. These findings contribute to a better knowledge of the desired vaccine-elicited immunity against T. cruzi and promote the definition of a vaccine correlate of protection against the infection.

show abstract

Recommendations of the Advisory Committee on Immunization Practices for Use of a Hepatitis B Vaccine with a Novel Adjuvant

Cited by 159 publications

References 8 publications

Chronic Viral Hepatitis: Current Management and Future Directions

Chronic Viral Hepatitis: Current Management and Future Directions

Advisory Committee on Immunization Practices recommended immunization schedule for children and adolescents aged 18 years or younger — United States, 2019

Mucosal Heterologous Prime/Boost Vaccination Induces Polyfunctional Systemic Immunity, Improving Protection Against Trypanosoma cruzi

Contact Info

Product

Resources

About